N
Nitika Sharma
Researcher at East Carolina University
Publications - 15
Citations - 279
Nitika Sharma is an academic researcher from East Carolina University. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 4, co-authored 15 publications receiving 177 citations. Previous affiliations of Nitika Sharma include Vidant Health.
Papers
More filters
Journal ArticleDOI
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Chipman Rg Stroud,Aparna Madhukeshwar Hegde,Cynthia R. Cherry,Abdul Rafeh Naqash,Nitika Sharma,Srikala Addepalli,Sulochana Devi Cherukuri,Teresa Parent,Jessica Hardin,Paul R. Walker +9 more
TL;DR: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade, however, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.
Journal ArticleDOI
Antibiotic use and overall survival in lung cancer patients receiving nivolumab.
Tien Phuc Do,Aparna Madhukeshwar Hegde,Cynthia R. Cherry,Chipman Robert Geoffrey Stroud,Nitika Sharma,Sulochana Devi Cherukuri,Mark R. Bowling,Paul R. Walker +7 more
TL;DR: The gut microbiome modulates immunotherapy responses in multiple tumor types and some studies report antibiotics (ATB) may alter the microbiota composi...
Journal ArticleDOI
Malignant pleural effusion and cancer of unknown primary site: a review of literature.
TL;DR: Given the poor prognosis associated with MPE from CUP, symptom alleviating measures such as indwelling pleural catheters should be part of the management strategy.
Journal ArticleDOI
Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors.
Nitika Sharma,Chipman Robert Geoffrey Stroud,Paul R. Walker,Cynthia R. Cherry,Sulochana Devi Cherukuri,Srikala Addepalli,Teresa Parent,Jessica Hardin +7 more
TL;DR: This data indicates that suppression of immune checkpoint blockade through EMT alone or a combination of EMT and chemotherapy is an attractive treatment option in a wide spectrum of malignancies.
Journal ArticleDOI
Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report.
Justin D. McCallen,Justin D. McCallen,Abdul Rafeh Naqash,Mona A. Marie,Druid C Atwell,Mahvish Muzaffar,Nitika Sharma,Suneetha Amara,Darla K. Liles,Paul R. Walker,Li V. Yang +10 more
TL;DR: In this paper, the authors proposed immune checkpoint inhibitors (ICIs) which suppress inhibitory signaling of several immune cell subtypes by the blocking the ligation of the checkpoint ligation, which is a breakthrough in therapy for many solid malignancies.